CTOs on the Move

Xeris Pharmaceuticals

www.xerispharma.com

 
It`s all about the experience. Everything we do is about simplifying and making things better and easier. It`s about making a difference in people`s lives.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.xerispharma.com
  • 180 North LaSalle Street Suite 1600
    Chicago, IL USA 60601
  • Phone: 844.445.5704

Executives

Name Title Contact Details
Curtis R
Manager of IT Infrastructure and Security Profile

Funding

Xeris Pharmaceuticals raised $41M on 01/07/2016
Xeris Pharmaceuticals raised $10M on 03/08/2018
Xeris Pharmaceuticals raised $45M on 03/08/2018
Xeris Pharmaceuticals raised $27M on 03/11/2021
Xeris Pharmaceuticals raised $30M on 01/03/2022

Similar Companies

Hi-Tech Pharmacal Co Inc

Hi-Tech Pharmacal Co Inc is a Amityville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innocoll

A specialty pharmaceutical company focused on the development and commercialization of pharmaceutical technologies to meet important healthcare challenges

Arizona Nutritional Supplements

Arizona Nutritional Supplements is a Chandler, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apexigen, Inc

Apexigen, Inc. is a privately held biopharmaceutical company discovering and developing innovative antibody therapeutics for the treatment of life-threatening and difficult-to-treat diseases. Using its proprietary antibody technology platform, Apexigen has discovered a pipeline of product candidates, which are currently at varying stages of development. The lead product candidate, APX005M, is a novel immuno-oncology antibody that stimulates and enhances an immune response against cancer. Apexigen is developing other product candidates in partnership with four leading biopharmaceutical companies in China. In addition, Apexigen has formed strategic partnerships with multi-national pharmaceutical companies, including Janssen Biotech, Alcon Laboratories and Toray Industries to discover first-in-class antibody lead candidates for the partners' programs.